The launch of MiniMed Mio Advance infusion set

On February 21, 2018, Medtronic (MDT) announced the launch of its MiniMed Mio Advance infusion set, the newest addition to its portfolio of MiniMed infusion sets. The device is used for insulin delivery from an insulin pump to a person’s body. The company plans to commercially launch the device in Canada, Hong Kong, and select European countries in fiscal 4Q18. In late 2018, Medtronic plans to expand the commercial availability of the device in other geographies around the world.

Medtronic Strengthens Diabetes Business with MiniMed Infusion Set

The device is part of Medtronic’s leading MiniMed products portfolio. The previous version, the MiniMed Mio, was launched in 2010.

Device features and benefits

The MiniMed Mio Advance infusion set has a user-friendly design and is easy to use. It has fewer steps and enables a simpler, faster set change. The device features a built-in insertion mechanism and a concealed needle. It can be inserted with one hand and offers flexibility to reach hard-to-reach sites such as the lower back.

Initial launch feedback

The device was selectively introduced by Medtronic in certain countries in fiscal 3Q18, which ended in January 2018. More than 200 people tried Medtronic’s MiniMed Mio infusion set during that period, and more than 85% of them found the device to be better than the infusion sets they were using previously.

According to Annette Brüls, president of Medtronic’s Diabetes Service and Solutions, “Early feedback on the Mio Advance infusion set has been fantastic. Our goal is to continuously improve and innovate on core technologies to help people with diabetes continue to experience greater freedom and better health. We are excited to leverage the MiniMed Mio Advance as a platform for future infusion set innovations.”

Abbott Laboratories (ABT) has also been actively expanding its diabetes business. It received FDA approval for its breakthrough continuous glucose monitoring (or CGM) device Freestyle Libre. It also launched a Freestyle Librelink app (application) in Europe in February 2018 for providing a better user experience. DexCom (DXCM) is expected to launch its CGM device by the end of 2018. However, Johnson & Johnson (JNJ) quit its insulin pump business in October 2017 amid intense competition.

Latest articles

Today, Canopy Growth announced that it acquired the Saskatchewan-based KeyLeaf Life Sciences along with entities relating to the company and its intellectual property. Here's what you need to know about the completed deal.

Yesterday, Tyson Foods (TSN) and fellow meat producers Pilgrim’s Pride (PPC) and Sanderson Farms (SAFM) took a hit to their stocks after news came out about an investigation over price-fixing allegations.

On June 24, RH (RH) was trading at $115.01, implying a rise of 21.2% since its announcement of its first-quarter earnings results on June 12. Despite the surge in its stock price, the company is still trading at a discount of 29.1% to its 52-week high.

26 Jun

Roku Stock Fell Close to 7.0% Yesterday

WRITTEN BY Aditya Raghunath

Roku stock fell 6.8% yesterday to close trading at $93.25 per share. Roku stock has lost over 9.0% in market value in the last two trading days. Prior to this pullback, Roku stock was up a whopping 235.0% year-to-date.

26 Jun

Beyond Meat Stock Up Today on New Product Launch

WRITTEN BY Rajiv Nanjapla

Today, Beyond Meat (BYND) announced that its new product, Beyond Beef, will hit markets across the US later this week.

FedEx (FDX) ended fiscal 2019 on a dismal note and reported a significant YoY decline in fourth-quarter earnings. The delivery giant posted adjusted EPS of $5.01, which was 15.2% lower than the year-ago quarter’s earnings of $5.91. The company cited sluggish revenue growth and increased expenses as the main reason behind the dismal bottom-line performance.

172.31.16.229